James has severe AD with night-time itch greatly disrupting his sleep

James works as a driving instructor and has severe AD. He has been struggling with a constant lack of sleep due to severe night itch over the past few weeks.

James needs to be alert for his work and is increasingy needing to take time off. He's becoming frustrated by his inability to focus due to disrupted sleep and exhaustion. 

He needs to find some quick relief for his itch and get back to having uninterrupted sleep.
  

CIBINQO 200 mg can offer rapid itch relief for patients like James whose lives are affected by AD²
CIBINQO 200 mg provided superior and rapid itch relief (PP-NRS4) compared to dupilumab²
     See JADE DARE Study Loading

Pinch to zoom

Randomised, double-blind, double-dummy, active-controlled trial comparing efficacy and safety of CIBINQO 200 mg + topical therapy* vs dupilumab + topical therapy*. Adult patients (n=727) with moderate-to-severe AD. Primary endpoints: PP-NRS4 response at Week 2; EASI-90 response at Week 4.

Data limitations: patients who withdrew from the study or used rescue therapy were considered as non-responders after that point. Intermittent missing values were not imputed.²

*Patients used medicated topical therapies in JADE DARE, including mild-to-moderate potency topical corticosteroids, topical calcineurin inhibitors or other available topical treatments, to treat active lesions, per protocol guidance.²

Tanvi has severe AD and wants lesions to clear up before her holiday 

Tanvi is looking forward to going on holiday with her friends in 4 weeks.

Tanvi's life has been impacted by severe AD, which has caused intense itching and painful lesions, affecting both her physical comfort and self-confidence.

She really wants the lesions to clear up before she goes on holiday.
  

CIBINQO 200 mg can offer clinically meaningful improvement in skin clearance (EASI-90) for those affected by moderate-to-severe AD^2,3*

Superior skin clearance (EASI-90) with CIBINQO 200 mg vs dupilumab at Week 4 and Week 16²
      See JADE DARE Study Loading

Pinch to zoom

Pinch to zoom

Randomised, double-blind, double-dummy, active-controlled trial comparing efficacy and safety of CIBINQO 200 mg + topical therapy* vs dupilumab + topical therapy*. Adult patients (n=727) with moderate-to-severe AD. Primary endpoints: PP-NRS4 response at Week 2; EASI-90 response at Week 4.

Data limitations: patients who withdrew from the study or used rescue therapy were considered as non-responders after that point. Intermittent missing values were not imputed.²
† Plus topical therapy. *Patients used medicated topical therapies in JADE DARE, including mild-to-moderate-potency topical corticosteroids, topical calcineurin inhibitors or other available topical treatments, to treat active lesions, per protocol guidance.²

Michael has significant head and neck lesions that make him self-conscious at work
Michael works as a hotel concierge and loves chatting with guests at the reception desk.

They are affecting his work, making him stressed, embarrassed and highly self-conscious that hotel guests and colleagues may be staring at them.

He is desperate for his head and neck lesions to visibly improve.

CIBINQO 200 mg led to almost complete skin clearance (EASI-90) of the head and neck region⁴
Post hoc analysis of JADE COMPARE⁴

Pinch to zoom

Pinch to zoom

JADE COMPARE is a multicentre, randomised, double blind phase 3 study. Primary endpoints were IGA 0/1 response with an improvement of ≥2 points from baseline and EASI-75 response at week 12 vs placebo.⁶

*Least squares mean percentage change from baseline in EASI head and neck score.⁴
† Post hoc analysis of data from the Phase 3 JADE COMPARE trial to investigate the temporal and regional patterns of clinical improvement in AD with CIBINQO.⁴